Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$7.72 -4.7%	$9.50	$3.75 ▼ $11.54	$130.90M	2.72	70,954 shs	86,938 shs
AKTX Akari Therapeutics	$0.89 -4.0%	$1.08	$0.85 ▼ $4.00	$29.65M	0.22	39,706 shs	76,477 shs
ALTS ALT5 Sigma	$6.80 +3.5%	$7.40	$1.55 ▼ $10.95	$141.97M	2.17	10.04 million shs	18.07 million shs
CLYM Climb Bio	$2.48 +4.2%	$1.53	$1.05 ▼ $8.79	$161.28M	-0.11	812,474 shs	1.05 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	0.00%	+1.25%	-18.76%	-11.38%	+809,999,900.00%
AKTX Akari Therapeutics	0.00%	-8.75%	-16.61%	-27.73%	-76.00%
ALTS ALT5 Sigma	0.00%	+10.61%	-7.20%	-26.26%	+158.66%
CLYM Climb Bio	0.00%	+25.26%	+64.14%	+101.69%	+237,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACOG Alpha Cognition	2.3214 of 5 stars	3.5	0.0	2.7	2.5	0.0
AKTX Akari Therapeutics	2.3038 of 5 stars	3.5	3.0	0.6	3.3	0.0
ALTS ALT5 Sigma	0.4143 of 5 stars	0.0	4.0	2.2	0.0	0.0
CLYM Climb Bio	3.3727 of 5 stars	3.7	0.0	3.2	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACOG Alpha Cognition	3.00	Buy	$20.00	159.07% Upside
AKTX Akari Therapeutics	3.00	Buy	$5.00	464.97% Upside
ALTS ALT5 Sigma	0.00	N/A	N/A	N/A
CLYM Climb Bio	3.33	Buy	$9.00	262.90% Upside

Current Analyst Ratings Breakdown

Latest AKTX, CLYM, ALTS, and ACOG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	CLYM Climb Bio	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/15/2025	CLYM Climb Bio	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
7/18/2025	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
6/6/2025	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	$2.59 per share	N/A
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$0.84 per share	N/A
ALTS ALT5 Sigma	$12.53M	11.73	N/A	N/A	$0.49 per share	13.88
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.15 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACOG Alpha Cognition	-$14.64M	-$1.60	N/A	∞	N/A	N/A	-80.16%	-60.95%	11/13/2025 (Estimated)
AKTX Akari Therapeutics	-$19.79M	N/A	0.00	∞	N/A	N/A	-78.03%	-31.62%	9/25/2025 (Estimated)
ALTS ALT5 Sigma	-$6.24M	N/A	0.00	∞	N/A	-74.89%	-179.27%	-16.28%	N/A
CLYM Climb Bio	-$73.90M	-$0.70	N/A	N/A	N/A	N/A	-23.10%	-22.47%	11/11/2025 (Estimated)

Latest AKTX, CLYM, ALTS, and ACOG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	ACOG Alpha Cognition	-$0.46	-$0.65	-$0.19	-$0.65	$2.32 million	$1.66 million
8/12/2025	Q2 2025	CLYM Climb Bio	-$0.19	-$0.13	+$0.06	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	N/A
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
ALTS ALT5 Sigma	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACOG Alpha Cognition	N/A	17.14	16.83
AKTX Akari Therapeutics	N/A	0.19	0.19
ALTS ALT5 Sigma	1.45	0.88	0.88
CLYM Climb Bio	N/A	14.08	14.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACOG Alpha Cognition	N/A
AKTX Akari Therapeutics	5.06%
ALTS ALT5 Sigma	6.27%
CLYM Climb Bio	69.76%

Insider Ownership

Company	Insider Ownership
ACOG Alpha Cognition	14.00%
AKTX Akari Therapeutics	38.10%
ALTS ALT5 Sigma	4.90%
CLYM Climb Bio	0.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACOG Alpha Cognition	N/A	16.16 million	13.90 million	N/A
AKTX Akari Therapeutics	9	32.18 million	19.92 million	Not Optionable
ALTS ALT5 Sigma	170	21.61 million	20.55 million	N/A
CLYM Climb Bio	9	67.76 million	65.60 million	N/A

AKTX, CLYM, ALTS, and ACOG Headlines

Recent News About These Companies

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

August 25 at 2:41 PM | globenewswire.com

Climb Bio to Present at Upcoming September 2025 Investor Conferences

August 25 at 7:00 AM | globenewswire.com

Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year?

August 20, 2025 | zacks.com

Climb Bio (NASDAQ:CLYM) Rating Increased to Strong-Buy at Baird R W

August 18, 2025 | marketbeat.com

Climb Bio (NASDAQ:CLYM) Coverage Initiated at Robert W. Baird

August 18, 2025 | americanbankingnews.com

Analysts Set Climb Bio, Inc. (NASDAQ:CLYM) Target Price at $9.00

August 18, 2025 | americanbankingnews.com

Climb Bio, Inc. (NASDAQ:CLYM) surges 12%; private equity firms who own 54% shares profited along with institutions

August 17, 2025 | finance.yahoo.com

Q3 Earnings Forecast for Climb Bio Issued By Leerink Partnrs

August 17, 2025 | marketbeat.com

Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of "Buy" from Analysts

August 17, 2025 | marketbeat.com

Climb Bio (NASDAQ:CLYM) Now Covered by Robert W. Baird

August 17, 2025 | marketbeat.com

Climb Bio (NASDAQ:CLYM) Raised to Strong-Buy at Baird R W

August 17, 2025 | americanbankingnews.com

What is Leerink Partnrs' Estimate for Climb Bio Q3 Earnings?

August 17, 2025 | americanbankingnews.com

Baird Initiates Coverage of Climb Bio (CLYM) with Outperform Recommendation

August 16, 2025 | msn.com

Climb Bio initiated with an Outperform at Baird on budoprutug potential

August 15, 2025 | msn.com

Climb Bio initiated with an Outperform at Baird

August 14, 2025 | msn.com

Climb Bio (NASDAQ:CLYM) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS

August 13, 2025 | marketbeat.com

Climb Bio, Inc.: Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 12, 2025 | finanznachrichten.de

Climb Bio reports Q2 EPS (13c) vs ($1.81) last year

August 12, 2025 | msn.com

Climb Bio, Inc. Advances Clinical Trials for Budoprutug in ITP and SLE, with Upcoming Initiation of pMN Trial and CLYM116 Webcast Event

August 12, 2025 | quiverquant.comQ

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 12, 2025 | globenewswire.com

Climb Bio (CLYM) Expected to Announce Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX, CLYM, ALTS, and ACOG Company Descriptions

Alpha Cognition NASDAQ:ACOG

$7.72 -0.38 (-4.69%)

As of 04:00 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Akari Therapeutics NASDAQ:AKTX

$0.88 -0.04 (-3.96%)

Closing price 03:51 PM Eastern

Extended Trading

$0.89 +0.01 (+0.56%)

As of 04:10 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

ALT5 Sigma NASDAQ:ALTS

$6.80 +0.23 (+3.50%)

Closing price 04:00 PM Eastern

Extended Trading

$6.75 -0.05 (-0.72%)

As of 07:59 PM Eastern

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Climb Bio NASDAQ:CLYM

$2.48 +0.10 (+4.20%)

As of 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time